Abstract
Introduction
A disproportionate number of hospitalized patients experience hyperglycemia. (1,2) Substantial risk is associated with inpatient hyper-and hypoglycemia due to diabetes and stress hyperglycemia. This has led to ongoing efforts to maintain glucose control in hospitalized patients. (1, 3) Three typical hyperglycemic patterns exist in hospitalized patients: diabetes that is known/previously diagnosed; undiagnosed diabetes identified during hospitalization; and hospital-related hyperglycemia (also known as stress hyperglycemia). Stress hyperglycemia presents during hospitalization, but often reverts to normoglycemia following discharge. (4) Hypoglycemia during hospitalization is also associated with increased mortality, longer length of stay (LOS), and an elevated risk of intensive care unit (ICU) admission in both insulin-treated and non-insulin-treated patients. (5, 6) Research indicates that approximately 8% of admitted patients will experience at least 1 hypoglycemic event. variability (GV), defined as the overall distribution of glucose values around the mean, is an emergent risk factor that has been independently associated with increased mortality. (8) In-hospital hyperglycemia is an independent predictor of morbidity and mortality, and its appropriate management improves patient outcomes. (2, (9) (10) (11) In a 2002 study, Umpierrez and colleagues found patients with hyperglycemia (on admission or in-hospital diagnosis) and no history of known diabetes were 29% more likely to be admitted to the intensive care unit (ICU), and experienced a 16% mortality rate. (2) In 2001, Van Den Berghe and colleagues found that critically ill patients treated to target BG levels 80 to 110 mg/dL had a 32% mortality reduction compared to those with BG maintained at 180 to 200 mg/dL (P<0.04). (9) Subsequent to this initial research, our understanding of ideal in-hospital glucose targets has been further refined.
The Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm
Regulation (NICE-SUGAR), a randomized controlled trial of more than 6,000 patients, found that lowering BG to <108 mg/dL in the ICU resulted in increased mortality (27.5%) over the control group, in which intermediate BG control (140 to 180 mg/dL) was maintained (24.9%; P=0.02). (10, 11) Likewise, during and after cardiac surgery, maintaining BG control <180 mg/dL reduces mortality, morbidity, reduces length of stay (LOS), and improves long-term survival. (12) In a study of patients undergoing open-heart surgery, elevated BG levels were independent predictors of mortality (P<0.0001), LOS (P<0.002), and post-operative sternal infections (P=0.017). (13) These data suggest that the association between BG and hospital mortality forms a J-curve, with euglycemia having the lowest mortality rate vs. both hyperglycemia and hypoglycemia. Substantial evidence indicates that blood glucose (BG) management using protocol-driven insulin administration leads to improved patient outcomes. (13) (14) (15) Typically, intravenous (IV) insulin infusion is the preferred management strategy, especially for critically ill patients, (1, 16) and several published protocols are available to guide IV insulin infusion administration. (13, 17, 18) In a study comparing cardiac surgery patients with BG controlled via subcutaneous injection vs. a protocol-based continuous infusion, use of the IV protocol led to a 2.5-fold decrease in post-operative complications such as sternal infection (P=0.011). (14) IV insulin protocol use has also been associated with substantial per-patient cost savings. (19) In 2006, the American College of Endocrinology (ACE) and the American Diabetes Association (ADA) recommended that insulin protocols, algorithms, and/or order sets be used to manage hyperglycemia and hypoglycemia in the hospital setting. (1) Until recently, hospitals were limited to paper-based IV insulin infusion protocol management.
In the last decade, however, computerized approaches, known as electronic glycemic management systems (eGMS), have become available. This has led to a growing literature base evaluating computerized insulin delivery mechanisms in the hospital setting. The past decade has seen substantial research to describe the performance of computer-programmed protocols (20, 21) and a series of controlled studies have found significantly improved BG control with eGMS vs.
paper-based protocols. (22) (23) (24) (25) (26) (27) (28) (29) This retrospective observational study was designed to evaluate the 7-year impact of an eGMS on patient hyperglycemia and hypoglycemia at Vidant Medical Center (VMC). EndoTool integrates with hospital information systems to manage IV insulin delivery. Using mathematical modeling and feedback controls, this eGMS analyzes BG reading trends to develop patient-specific physiologic insulin dosing curves based on patient weight, age, diabetes type, and glomerular filtration rate (Figure 1) . Clinician-inputted, patient-specific information is used to calculate the optimal timing of both fingerstick BG checks and appropriate IV insulin dosing, Prior to implementing eGMS, VMC initiated a multistep assessment process that included:
interdisciplinary review of failed cases; identification of a standardized IV continuous infusion protocol; selection of an appropriate computerized management tool; and action step generation.
Patients and Outcomes Evaluated
This retrospective observational study evaluated the 7-year impact ( 
Analytics
Individual patient data were generated by the eGMS's analytic function. Year-by-year comparisons of patient data samples were analyzed using one-way analysis of variance (ANOVA). Glucose variability was assessed using mean BG data to identify the SD of BG measurements for each patient visit, followed by CV calculation, expressed as a percentage. Cumulative data were analyzed using descriptive statistics only. VMC HAC-8 data were compared with national data obtained from CMS.
Results
Data were available for 100% of treated patients. Over 7 years, 492,078 BG readings were obtained from 16,850 patients, for an average of 29 readings per patient. As shown in Table 3 , between 2009 and 2015, the eGMS was able to bring hyperglycemic patients to glucose levels <180 mg/dL within 1.5 to 2.3 hours. Among evaluable patient records, only 4% showed glucose excursions (>180 mg/dL) after prior glucose control was achieved; the average duration of a glucose excursion was 1.91 hours. In terms of GV, the mean BG ± SD was 143 ± 39.9 mg/dL on average per patient visit, with an average CV per patient visit of 26.5 (±12.9)%.
Data from VMC cardiovascular surgery units are shown in VMC patients also experienced a relatively rapid time to BG control <180 mg/dL (1.5 to 2.3 hours) and a very low rate (0.4%) of glucose excursions (defined as BG levels >180 mg/dL once control was attained). Additionally, the overall rate of GV (calculated as CV%) was 26.5% (±12.9). To put this finding in context, in 2011 Rodbard identified CV% levels <33.5% as "excellent." (36) Additionally, the CV% observed in this multi-site study were substantially lower than hospital-level mean CV% analyzed in a similar fashion by two recent single-site parameters are all independently associated with higher in-hospital mortality rates and length of stay, (2, 7, 8) and have all been shown to improve with eGMS compared with paper-based protocols, both in previous studies (23, 25, 26, 28, 39) and the current analysis.
VMC's success mirrors other sites' experience with the EndoTool eGMS. Two prior randomized studies and a retrospective analysis have found that, in eGMS-managed surgical ICU patients, the number of BG measurements falling within target range significantly improved and BG excursions significantly decreased compared with paper protocol management. (23, 28, 39) Likewise, the use of this eGMS to manage BG levels in critically ill surgical ICU patients has been associated with a decreased frequency of serious hypo-and hyperglycemia. (26) Another study reported that the mean time free from severe hypoglycemia following cardiovascular ICU discharge was 7.0 days for patients treated with eGMS and 1.1 days for paper protocol-treated patients. (25) DOI:10.4158/EP161402.OR © 2016 AACE.
The EndoTool eGMS uses an algorithm comprising clinician-inputted, patient-specific information to calculate the optimal timing of both fingerstick BG checks and appropriate insulin infusion dosing. Each BG reading and insulin dose is entered into the system, allowing the algorithm to re-calculate as needed. The resulting individualized insulin dosage curve helps to minimize hyperglycemia, hypoglycemia, and glucose excursions. Furthermore, this system can typically be integrated into electronic health record systems and/or order entry menus, eliminating the need for paper or printed protocols. EndoTool is a U.S. Food and Drug
Administration-approved eGMS that uses patented modeling with individualized feedback to maintain glycemic control. (40) To evaluate performance, the system provides patient-and unitspecific reporting capabilities and post-use analytics. (39)
Limitations
This study is one of the largest and longest retrospective analyses of eGMS data conducted to date; it also reflects a range of patients with varying characteristics on admission. The primary limitation of this study is that it was a retrospective, single center analysis. Based on this, it is difficult to know whether other variables or heterogeneity between the multiple units analyzed influenced outcomes. Ideally, future studies will evaluate patient outcomes both prior to and following eGMS implementation. However, the observed improved glucose outcomes, and the similarity of these results with prior research findings, argue in favor of a positive relationship between eGMS use and improved BG control. controlled research examining the relationship between time to BG target and patient outcomes will help clinicians to even further refine in-hospital hyperglycemia management. Last, the impact of BG management with eGMS in specific high-risk patient groups should be evaluated (for example, following coronary artery bypass grafting or in patients with diabetic ketoacidosis).
Conclusion
The use of an eGMS to manage glucose levels in hospitalized patients with diabetes may lead to improved glycemic control, and therefore better patient outcomes. VMC's use of the eGMS to administer IV insulin in the ICUs and IUs in the setting of a large tertiary care hospital resulted in significant improvements in overall glucose control, assessed as hyperglycemia, hypoglycemia, and glucose excursions. It is likely that other facilities could achieve similar improvements in BG control and patient outcomes using the EndoTool eGMS. Linear protocols dose insulin based on an initial blood glucose reading. As readings continue, insulin continues to be administered without accounting for previously administered insulin. If/when a patient reaches a blood glucose target range, the patient is at risk for a hypoglycemia event as a result of residual and active insulin.
B: EndoTool
EndoTool initiates the first insulin dose based on multiple patient variables (including the blood glucose reading). EndoTool then develops a trend to model and predict the patient response in order to reduce the amount of insulin administered, thus bringing the patient safely to control.
----------- In this image, the nurse selects patient with a previous BG value of 155 mg/dL. The nurse enters a new BG level (133 mg/dL), which will be used by the system to adjust the patient's insulin drip and move the patient safely towards goal range (90 mg/dL to 120 mg/dL). When appropriate, the nurse indicates if the patient has eaten a meal or snack (so the system may adjust for additional carbohydrates).
2b. The nurse confirms the recommended insulin drip rate that coincides with the BG entered. EndoTool will use the inputted BG value and patient's physiologic data to make a new insulin dosing recommendation and set the frequency for the next BG Check.
----------- ----------- 
